# Official Journal C 24/2009

| | ISSN 1725-2423 |
| --- | --- |
| Official Journal
  of the European Union | C 24 |
| | |
| English edition | Information and Notices | Volume 5230 January 2009 |

ISSN 1725-2423

Official Journal

of the European Union

C 24

English edition

Information and Notices

Volume 5230 January 2009

---

| Notice No | Contents | page |
| --- | --- | --- |
| | II   Information |
| | INFORMATION FROM EUROPEAN UNION INSTITUTIONS AND BODIES |
| | Commission |
| 2009/C 024/01 | Non-opposition to a notified concentration (Case COMP/M.5346 — APMM/Broström) (
  1
  ) | 1 |
| 2009/C 024/02 | Non-opposition to a notified concentration (Case COMP/M.5415 — Telenet/Concentra/VAR/JV) (
  1
  ) | 1 |
| 2009/C 024/03 | Non-opposition to a notified concentration (Case COMP/M.5341 — Allianz/Cominvest) (
  1
  ) | 2 |

Notice No

Contents

page

II   Information

INFORMATION FROM EUROPEAN UNION INSTITUTIONS AND BODIES

Commission

2009/C 024/01

Non-opposition to a notified concentration (Case COMP/M.5346 — APMM/Broström) (
  1
  )

1

1

2009/C 024/02

Non-opposition to a notified concentration (Case COMP/M.5415 — Telenet/Concentra/VAR/JV) (
  1
  )

1

1

2009/C 024/03

Non-opposition to a notified concentration (Case COMP/M.5341 — Allianz/Cominvest) (
  1
  )

1

2

| | IV   Notices |
| --- | --- |
| | NOTICES FROM EUROPEAN UNION INSTITUTIONS AND BODIES |
| | Council |
| 2009/C 024/04 | Council conclusions concerning joint programming of research in Europe in response to major societal challenges | 3 |
| | Commission |
| 2009/C 024/05 | Euro exchange rates | 7 |
| 2009/C 024/06 | Summary of Community decisions on marketing authorizations in respect of medicinal products from 1 December 2008 to 31 December 2008(Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council
  ) | 8 |

IV   Notices

NOTICES FROM EUROPEAN UNION INSTITUTIONS AND BODIES

Council

2009/C 024/04

Council conclusions concerning joint programming of research in Europe in response to major societal challenges

3

Commission

2009/C 024/05

Euro exchange rates

7

2009/C 024/06

Summary of Community decisions on marketing authorizations in respect of medicinal products from 1 December 2008 to 31 December 2008(Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council
  )

(Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council

)

8

| | V   Announcements |
| --- | --- |
| | PROCEDURES RELATING TO THE IMPLEMENTATION OF THE COMPETITION POLICY |
| | Commission |
| 2009/C 024/07 | Prior notification of a concentration (Case COMP/M.5355 — BASF/Ciba) (
  1
  ) | 14 |
| 2009/C 024/08 | Prior notification of a concentration (Case COMP/M.5432 — Credit Mutuel/Cofidis) (
  1
  ) | 15 |
| 2009/C 024/09 | Prior notification of a concentration (Case COMP/M.5471 — Goldman Sachs/Constellation Energy Commodities) — Candidate case for simplified procedure (
  1
  ) | 16 |
| 2009/C 024/10 | Prior notification of a concentration (Case COMP/M.5370 — CEZ/Akkok/Sedas/Akenerji) — Candidate case for simplified procedure (
  1
  ) | 17 |

V   Announcements

PROCEDURES RELATING TO THE IMPLEMENTATION OF THE COMPETITION POLICY

Commission

2009/C 024/07

Prior notification of a concentration (Case COMP/M.5355 — BASF/Ciba) (
  1
  )

1

14

2009/C 024/08

Prior notification of a concentration (Case COMP/M.5432 — Credit Mutuel/Cofidis) (
  1
  )

1

15

2009/C 024/09

Prior notification of a concentration (Case COMP/M.5471 — Goldman Sachs/Constellation Energy Commodities) — Candidate case for simplified procedure (
  1
  )

1

16

2009/C 024/10

Prior notification of a concentration (Case COMP/M.5370 — CEZ/Akkok/Sedas/Akenerji) — Candidate case for simplified procedure (
  1
  )

1

17

| | |
| --- | --- |
| 2009/C 024/11 | Note to the reader(see page 3 of the cover) | s3 |

2009/C 024/11

Note to the reader(see page 3 of the cover)

Note to the reader

s3

| | |
| --- | --- |
| | (1)   Text with EEA relevance |

---

(1)   Text with EEA relevance

1

| EN | |
| --- | --- |

EN

---

II Information

INFORMATION FROM EUROPEAN UNION INSTITUTIONS AND BODIES

Commission

| 30.1.2009 | EN | Official Journal of the European Union | C 24/1 |
| --- | --- | --- | --- |

30.1.2009

EN

Official Journal of the European Union

C 24/1

---

Non-opposition to a notified concentration

(Case COMP/M.5346 — APMM/Broström)

(Text with EEA relevance)

(2009/C 24/01)

On 14 January 2009, the Commission decided not to oppose the above notified concentration and to declare it compatible with the common market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004. The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

| — | from the Europa competition website (http://ec.europa.eu/comm/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes, |
| --- | --- |

—

from the Europa competition website (http://ec.europa.eu/comm/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

| — | in electronic form on the EUR-Lex website under document number 32009M5346. EUR-Lex is the on-line access to European law (http://eur-lex.europa.eu). |
| --- | --- |

—

in electronic form on the EUR-Lex website under document number 32009M5346. EUR-Lex is the on-line access to European law (http://eur-lex.europa.eu).

---

| 30.1.2009 | EN | Official Journal of the European Union | C 24/1 |
| --- | --- | --- | --- |

30.1.2009

EN

Official Journal of the European Union

C 24/1

---

Non-opposition to a notified concentration

(Case COMP/M.5415 — Telenet/Concentra/VAR/JV)

(Text with EEA relevance)

(2009/C 24/02)

On 21 January 2009, the Commission decided not to oppose the above notified concentration and to declare it compatible with the common market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004. The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

| — | from the Europa competition website (http://ec.europa.eu/comm/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes, |
| --- | --- |

—

from the Europa competition website (http://ec.europa.eu/comm/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

| — | in electronic form on the EUR-Lex website under document number 32009M5415. EUR-Lex is the on-line access to European law (http://eur-lex.europa.eu). |
| --- | --- |

—

in electronic form on the EUR-Lex website under document number 32009M5415. EUR-Lex is the on-line access to European law (http://eur-lex.europa.eu).

---

| 30.1.2009 | EN | Official Journal of the European Union | C 24/2 |
| --- | --- | --- | --- |

30.1.2009

EN

Official Journal of the European Union

C 24/2

---

Non-opposition to a notified concentration

(Case COMP/M.5341 — Allianz/Cominvest)

(Text with EEA relevance)

(2009/C 24/03)

On 18 December 2008, the Commission decided not to oppose the above notified concentration and to declare it compatible with the common market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004. The full text of the decision is available only in German and will be made public after it is cleared of any business secrets it may contain. It will be available:

| — | from the Europa competition website (http://ec.europa.eu/comm/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes, |
| --- | --- |

—

from the Europa competition website (http://ec.europa.eu/comm/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

| — | in electronic form on the EUR-Lex website under document number 32008M5341. EUR-Lex is the on-line access to European law (http://eur-lex.europa.eu). |
| --- | --- |

—

in electronic form on the EUR-Lex website under document number 32008M5341. EUR-Lex is the on-line access to European law (http://eur-lex.europa.eu).

---

IV Notices

NOTICES FROM EUROPEAN UNION INSTITUTIONS AND BODIES

Council

| 30.1.2009 | EN | Official Journal of the European Union | C 24/3 |
| --- | --- | --- | --- |

30.1.2009

EN

Official Journal of the European Union

C 24/3

---

Council conclusions concerning joint programming of research in Europe in response to major societal challenges

(2009/C 24/04)

THE COUNCIL OF THE EUROPEAN UNION,

RECALLING:

| — | its resolution on CREST (28 September 1995) (1), which authorises this committee in particular to ‘promote the coordination by the Community and the Member States of their R & D activities in order to ensure mutual consistency between the national policies and Community policy’, |
| --- | --- |

—

its resolution on CREST (28 September 1995) (1), which authorises this committee in particular to ‘promote the coordination by the Community and the Member States of their R & D activities in order to ensure mutual consistency between the national policies and Community policy’,

| — | its resolutions on the creation of the European area of research and innovation (15 June 2000) and on the realisation of the European Research Area: orientations for EU action in the field of research (2002-2006) (16 November 2000), |
| --- | --- |

—

its resolutions on the creation of the European area of research and innovation (15 June 2000) and on the realisation of the European Research Area: orientations for EU action in the field of research (2002-2006) (16 November 2000),

| — | its conclusions on progress accomplished in the development of the European Research Area and on providing a new momentum (26 November 2002), |
| --- | --- |

—

its conclusions on progress accomplished in the development of the European Research Area and on providing a new momentum (26 November 2002),

| — | the Commission Green Paper on ‘The European Research Area: New Perspectives’, |
| --- | --- |

—

the Commission Green Paper on ‘The European Research Area: New Perspectives’,

| — | its conclusions on the future of science and technology in Europe (23 November 2007), |
| --- | --- |

—

its conclusions on the future of science and technology in Europe (23 November 2007),

| — | its conclusions on the Commission communication ‘A European Strategic Energy Technology Plan (SET Plan) — Towards a low-carbon future’ (28 February 2008), |
| --- | --- |

—

its conclusions on the Commission communication ‘A European Strategic Energy Technology Plan (SET Plan) — Towards a low-carbon future’ (28 February 2008),

| — | its conclusions on the launch of the ‘Ljubljana process’ — realisation of the European Research Area (30 May 2008), |
| --- | --- |

—

its conclusions on the launch of the ‘Ljubljana process’ — realisation of the European Research Area (30 May 2008),

| — | its conclusions concerning ‘A common commitment by the Member States to combat neurodegenerative diseases, particularly Alzheimer's’ (26 September 2008), |
| --- | --- |

—

its conclusions concerning ‘A common commitment by the Member States to combat neurodegenerative diseases, particularly Alzheimer's’ (26 September 2008),

| — | its Key Issues Paper (KIP) for 2008: Contribution of the Competitiveness Council to the Spring European Council (25 February 2008), in which Member States and the Commission were encouraged to continue developing initiatives for joint programming of research in areas suited to such an approach, allowing a more strategic and better structured approach to the launch of new joint programmes and common calls for projects, |
| --- | --- |

—

its Key Issues Paper (KIP) for 2008: Contribution of the Competitiveness Council to the Spring European Council (25 February 2008), in which Member States and the Commission were encouraged to continue developing initiatives for joint programming of research in areas suited to such an approach, allowing a more strategic and better structured approach to the launch of new joint programmes and common calls for projects,

| — | the conclusions of the European Council of 13 and 14 March 2008, which launched the new cycle of the Lisbon strategy for growth and jobs (2008-2010) and which, with the aim of fully developing the potential for innovation and creativity of European citizens, confirmed that particular attention should be given to further initiatives for joint programming of research; |
| --- | --- |

—

the conclusions of the European Council of 13 and 14 March 2008, which launched the new cycle of the Lisbon strategy for growth and jobs (2008-2010) and which, with the aim of fully developing the potential for innovation and creativity of European citizens, confirmed that particular attention should be given to further initiatives for joint programming of research;

| 1. | RECOGNISES that, in the context of globalisation and the intensification of global competition, there has been a growing awareness in Europe of the existence of common societal challenges which no Member State is capable of resolving alone. Certain issues related to, for example, climate change, the ageing of the population, energy, water or food supplies, banking finances and security (2) are now of such a magnitude that Europe needs to elaborate a stronger, better coordinated, more coherent and more global response to these challenges; |
| --- | --- |

1.

RECOGNISES that, in the context of globalisation and the intensification of global competition, there has been a growing awareness in Europe of the existence of common societal challenges which no Member State is capable of resolving alone. Certain issues related to, for example, climate change, the ageing of the population, energy, water or food supplies, banking finances and security (2) are now of such a magnitude that Europe needs to elaborate a stronger, better coordinated, more coherent and more global response to these challenges;

| 2. | RECALLS the large volume of public resources committed to research and innovation in the various Member States, including at regional level, and UNDERLINES the need for and the potential of scientific, financial and human resources for increased cooperation between Member States, through the implementation of common initiatives aimed at addressing major societal challenges, in order to strengthen Europe's capacity to transform the results of its research into tangible benefits for society and for the overall competitiveness of its economy; |
| --- | --- |

2.

RECALLS the large volume of public resources committed to research and innovation in the various Member States, including at regional level, and UNDERLINES the need for and the potential of scientific, financial and human resources for increased cooperation between Member States, through the implementation of common initiatives aimed at addressing major societal challenges, in order to strengthen Europe's capacity to transform the results of its research into tangible benefits for society and for the overall competitiveness of its economy;

| 3. | UNDERLINES the important role of the Community Framework Programme for Research and Technological Development (FP) and the related instruments, such as ERA-NET, ERA-NET + and the initiatives under Article 169, in mobilising Member States' scientific and financial resources for implementing R & D initiatives of common interest, and ENCOURAGES their continued use in the context of joint responses to tackle major societal challenges; |
| --- | --- |

3.

UNDERLINES the important role of the Community Framework Programme for Research and Technological Development (FP) and the related instruments, such as ERA-NET, ERA-NET + and the initiatives under Article 169, in mobilising Member States' scientific and financial resources for implementing R & D initiatives of common interest, and ENCOURAGES their continued use in the context of joint responses to tackle major societal challenges;

| 4. | RECOGNISES also the importance of existing activities aimed at coordinating programmes conducted by national agencies and research organisations in several Member States, including at regional level, and by international organisations, as well as other cross-border and intergovernmental initiatives in this context (EUREKA, COST); and ENCOURAGES their continued use; |
| --- | --- |

4.

RECOGNISES also the importance of existing activities aimed at coordinating programmes conducted by national agencies and research organisations in several Member States, including at regional level, and by international organisations, as well as other cross-border and intergovernmental initiatives in this context (EUREKA, COST); and ENCOURAGES their continued use;

| 5. | RECOGNISES that in addition to the existing regional, national, intergovernmental and Community instruments to pool or coordinate national R & D efforts, there is an increasing need for a new and more strategic approach. This approach should be based on the joint identification of societal challenges of common interest and a strengthened political commitment by Member States to produce common or concerted responses, in order to increase the efficiency and the effectiveness of public R & D funding in Europe; |
| --- | --- |

5.

RECOGNISES that in addition to the existing regional, national, intergovernmental and Community instruments to pool or coordinate national R & D efforts, there is an increasing need for a new and more strategic approach. This approach should be based on the joint identification of societal challenges of common interest and a strengthened political commitment by Member States to produce common or concerted responses, in order to increase the efficiency and the effectiveness of public R & D funding in Europe;

| 6. | In this context, WELCOMES the concept and objectives of joint programming as formulated in the communication of the Commission ‘Towards joint Programming research: Working together to tackle common challenges more effectively’, which calls for the implementation of a process led by the Member States to step up their cooperation in the R & D area in order to better confront major societal challenges of European or worldwide scale, where public research plays a key role; |
| --- | --- |

6.

In this context, WELCOMES the concept and objectives of joint programming as formulated in the communication of the Commission ‘Towards joint Programming research: Working together to tackle common challenges more effectively’, which calls for the implementation of a process led by the Member States to step up their cooperation in the R & D area in order to better confront major societal challenges of European or worldwide scale, where public research plays a key role;

| 7. | UNDERLINES that, while fully recognising the competence of Member States and regions over their choice of research and innovation policies and related allocation of resources, the participation of Member States and FP associated countries in joint programming should be carried out on voluntary basis and according to the principle of variable geometry and open access. The participation in joint programming should also be based on scientific excellence and full utilisation of the research potential of its members; |
| --- | --- |

7.

UNDERLINES that, while fully recognising the competence of Member States and regions over their choice of research and innovation policies and related allocation of resources, the participation of Member States and FP associated countries in joint programming should be carried out on voluntary basis and according to the principle of variable geometry and open access. The participation in joint programming should also be based on scientific excellence and full utilisation of the research potential of its members;

| 8. | ENCOURAGES Member States, with the support of the Commission, to consider how best to address the following issues during the development and implementation of joint programming:






  — | a coherent approach on the peer review procedures, |
| --- | --- | --- |

8.

ENCOURAGES Member States, with the support of the Commission, to consider how best to address the following issues during the development and implementation of joint programming:

—

a coherent approach on the peer review procedures,

| — | a coherent approach for foresight activities and for evaluation of joint programmes, |
| --- | --- |

—

a coherent approach for foresight activities and for evaluation of joint programmes,

| — | a coherent approach to funding of cross-border research by national or regional authorities, |
| --- | --- |

—

a coherent approach to funding of cross-border research by national or regional authorities,

| — | effective measures to ensure the optimum dissemination and use of research findings, inter alia via common practices for the protection, management and sharing of intellectual property rights, |
| --- | --- |

—

effective measures to ensure the optimum dissemination and use of research findings, inter alia via common practices for the protection, management and sharing of intellectual property rights,

| — | involvement of the various scientific and, where appropriate, industry communities; |
| --- | --- |

—

involvement of the various scientific and, where appropriate, industry communities;

| 9. | CONSIDERS that the following criteria should help identify joint programming themes:






  — | there is a sufficient and effective commitment of Member States concerned, |
| --- | --- | --- |

9.

CONSIDERS that the following criteria should help identify joint programming themes:

—

there is a sufficient and effective commitment of Member States concerned,

| — | the theme addresses a European or global challenge and is sufficiently focused so that clear and realistic objectives can be laid down and followed up, |
| --- | --- |

—

the theme addresses a European or global challenge and is sufficiently focused so that clear and realistic objectives can be laid down and followed up,

| — | it brings a clear added value to overall current research financed from national and Community public funds, as regards both economies of scale and better thematic coverage, |
| --- | --- |

—

it brings a clear added value to overall current research financed from national and Community public funds, as regards both economies of scale and better thematic coverage,

| — | relevant regional, national and European stakeholders, including where appropriate the private sector besides scientific communities and funding agencies, have been involved in developing the theme, |
| --- | --- |

—

relevant regional, national and European stakeholders, including where appropriate the private sector besides scientific communities and funding agencies, have been involved in developing the theme,

| — | a joint programming approach has the potential of translating the output of good public research into benefits for European citizens and European competitiveness, and of increasing the efficiency and impact of public R & D financing by involving the key public initiatives in the area; |
| --- | --- |

—

a joint programming approach has the potential of translating the output of good public research into benefits for European citizens and European competitiveness, and of increasing the efficiency and impact of public R & D financing by involving the key public initiatives in the area;

| 10. | ASKS Member States to collaborate in a dedicated configuration of CREST (hereinafter referred to as ‘High Level Group for Joint Programming’ or GPC) to identify, in accordance with the mandate in the annex, the themes for joint programming chosen following broad public consultation of the different regional, national and European scientific communities, and of the private sector where appropriate.
  Taking account of the framework conditions laid down in paragraph 8, each thematic proposal presented to GPC by one or more of its members should include preliminary suggestions concerning a common vision, the governance and implementation of joint programming initiatives. GPC should evaluate each thematic proposal for joint programming on the basis of the criteria laid down in paragraph 9; |
| --- | --- |

10.

ASKS Member States to collaborate in a dedicated configuration of CREST (hereinafter referred to as ‘High Level Group for Joint Programming’ or GPC) to identify, in accordance with the mandate in the annex, the themes for joint programming chosen following broad public consultation of the different regional, national and European scientific communities, and of the private sector where appropriate.

Taking account of the framework conditions laid down in paragraph 8, each thematic proposal presented to GPC by one or more of its members should include preliminary suggestions concerning a common vision, the governance and implementation of joint programming initiatives. GPC should evaluate each thematic proposal for joint programming on the basis of the criteria laid down in paragraph 9;

| 11. | ASKS GPC to identify and substantiate the first list of a limited number of joint programming themes in due time; and INVITES the Commission, within the remit of its competence, to submit a proposal for a Council Recommendation in preparation for the launch of joint programming initiatives which correspond to the themes identified by the GPC, together with the state of play of research in the field of each of these themes, so that the Council is able to adopt joint programming initiatives no later than 2010; |
| --- | --- |

11.

ASKS GPC to identify and substantiate the first list of a limited number of joint programming themes in due time; and INVITES the Commission, within the remit of its competence, to submit a proposal for a Council Recommendation in preparation for the launch of joint programming initiatives which correspond to the themes identified by the GPC, together with the state of play of research in the field of each of these themes, so that the Council is able to adopt joint programming initiatives no later than 2010;

| 12. | UNDERLINES that joint programming is a process led by Member States, and that the Commission's role is to facilitate the process of identification and provide support as necessary; |
| --- | --- |

12.

UNDERLINES that joint programming is a process led by Member States, and that the Commission's role is to facilitate the process of identification and provide support as necessary;

| 13. | In this context, EMPHASISES the need to analyse the relevance and the potential of existing regional, national, Community and intergovernmental instruments for meeting the identified societal challenges, and INVITES the Commission to carry out such an examination in close cooperation with the other stakeholders and provide input on the most appropriate instruments to meet these challenges; |
| --- | --- |

13.

In this context, EMPHASISES the need to analyse the relevance and the potential of existing regional, national, Community and intergovernmental instruments for meeting the identified societal challenges, and INVITES the Commission to carry out such an examination in close cooperation with the other stakeholders and provide input on the most appropriate instruments to meet these challenges;

| 14. | CONSIDERS it necessary to launch a pilot joint programming initiative on combating neurodegenerative diseases, in particular Alzheimer's, and INVITES the Commission to submit a proposal for a Council Recommendation in preparation for the launch of this pilot initiative as soon as possible in 2009; |
| --- | --- |

14.

CONSIDERS it necessary to launch a pilot joint programming initiative on combating neurodegenerative diseases, in particular Alzheimer's, and INVITES the Commission to submit a proposal for a Council Recommendation in preparation for the launch of this pilot initiative as soon as possible in 2009;

| 15. | CONSIDERS that all procedures concerning joint programming of European research must be examined within the framework of the general approach to optimise the governance of the European Research Area, as provided by the Ljubljana Process; |
| --- | --- |

15.

CONSIDERS that all procedures concerning joint programming of European research must be examined within the framework of the general approach to optimise the governance of the European Research Area, as provided by the Ljubljana Process;

| 16. | INVITES CREST to report, in the context of these conclusions, to the Council on joint programming every two years: the first report is expected in 2010. |
| --- | --- |

16.

INVITES CREST to report, in the context of these conclusions, to the Council on joint programming every two years: the first report is expected in 2010.

---

(1)  OJ C 264, 11.10.1995, p. 4.

(2)  This list is without prejudice to themes for joint programming, which will be chosen at a later stage.

---

ANNEX

Mandate of the High Level Group on Joint Programming (GPC)

| 1. | GPC:






  (a) | is a dedicated configuration of CREST composed of high-level representatives of the Member States and of the Commission and, where appropriate, associated countries; |
| --- | --- | --- |

1.

GPC:

(a)

is a dedicated configuration of CREST composed of high-level representatives of the Member States and of the Commission and, where appropriate, associated countries;

| (b) | will be chaired by the representative of the Presidency-in-office of the Council; |
| --- | --- |

(b)

will be chaired by the representative of the Presidency-in-office of the Council;

| (c) | will be responsible for identifying according to a continuous process the possible themes for joint programming selected following broad consultation of the different regional, national and European scientific communities as well as, where appropriate, other public and private stakeholders mentioned in paragraph 10; |
| --- | --- |

(c)

will be responsible for identifying according to a continuous process the possible themes for joint programming selected following broad consultation of the different regional, national and European scientific communities as well as, where appropriate, other public and private stakeholders mentioned in paragraph 10;

| (d) | in this framework, will be responsible for evaluating each proposal submitted to it on the basis of the criteria in paragraph 9; |
| --- | --- |

(d)

in this framework, will be responsible for evaluating each proposal submitted to it on the basis of the criteria in paragraph 9;

| (e) | will contribute to the preparation of the debates and decisions of the Competitiveness Council on joint programming, within the mandate of CREST and without prejudice to the responsibilities of the Committee of Permanent Representatives; |
| --- | --- |

(e)

will contribute to the preparation of the debates and decisions of the Competitiveness Council on joint programming, within the mandate of CREST and without prejudice to the responsibilities of the Committee of Permanent Representatives;

| (f) | will initiate the consideration of issues referred to in paragraph 8. |
| --- | --- |

(f)

will initiate the consideration of issues referred to in paragraph 8.

| 2. | The Commission will support the work of GPC within the remit of its competence. |
| --- | --- |

2.

The Commission will support the work of GPC within the remit of its competence.

| 3. | The Member States will nominate their representatives at meetings of GPC before the end of January 2009. |
| --- | --- |

3.

The Member States will nominate their representatives at meetings of GPC before the end of January 2009.

---

Commission

| 30.1.2009 | EN | Official Journal of the European Union | C 24/7 |
| --- | --- | --- | --- |

30.1.2009

EN

Official Journal of the European Union

C 24/7

---

Euro exchange rates (1)

29 January 2009

(2009/C 24/05)

1 euro=

| | Currency | Exchange rate |
| --- | --- | --- |
| USD | US dollar | 1,3111 |
| JPY | Japanese yen | 118,07 |
| DKK | Danish krone | 7,4522 |
| GBP | Pound sterling | 0,91725 |
| SEK | Swedish krona | 10,5341 |
| CHF | Swiss franc | 1,5063 |
| ISK | Iceland króna | |
| NOK | Norwegian krone | 8,8 |
| BGN | Bulgarian lev | 1,9558 |
| CZK | Czech koruna | 27,48 |
| EEK | Estonian kroon | 15,6466 |
| HUF | Hungarian forint | 287,28 |
| LTL | Lithuanian litas | 3,4528 |
| LVL | Latvian lats | 0,6988 |
| PLN | Polish zloty | 4,384 |
| RON | Romanian leu | 4,243 |
| TRY | Turkish lira | 2,1229 |
| AUD | Australian dollar | 1,9942 |
| CAD | Canadian dollar | 1,5963 |
| HKD | Hong Kong dollar | 10,1696 |
| NZD | New Zealand dollar | 2,5294 |
| SGD | Singapore dollar | 1,9726 |
| KRW | South Korean won | 1 795,81 |
| ZAR | South African rand | 12,9979 |
| CNY | Chinese yuan renminbi | 8,9653 |
| HRK | Croatian kuna | 7,3711 |
| IDR | Indonesian rupiah | 14 913,76 |
| MYR | Malaysian ringgit | 4,7186 |
| PHP | Philippine peso | 61,37 |
| RUB | Russian rouble | 45,7293 |
| THB | Thai baht | 45,764 |
| BRL | Brazilian real | 2,9795 |
| MXN | Mexican peso | 18,5062 |
| INR | Indian rupee | 63,877 |

Currency

Exchange rate

USD

US dollar

1,3111

JPY

Japanese yen

118,07

DKK

Danish krone

7,4522

GBP

Pound sterling

0,91725

SEK

Swedish krona

10,5341

CHF

Swiss franc

1,5063

ISK

Iceland króna

NOK

Norwegian krone

8,8

BGN

Bulgarian lev

1,9558

CZK

Czech koruna

27,48

EEK

Estonian kroon

15,6466

HUF

Hungarian forint

287,28

LTL

Lithuanian litas

3,4528

LVL

Latvian lats

0,6988

PLN

Polish zloty

4,384

RON

Romanian leu

4,243

TRY

Turkish lira

2,1229

AUD

Australian dollar

1,9942

CAD

Canadian dollar

1,5963

HKD

Hong Kong dollar

10,1696

NZD

New Zealand dollar

2,5294

SGD

Singapore dollar

1,9726

KRW

South Korean won

1 795,81

ZAR

South African rand

12,9979

CNY

Chinese yuan renminbi

8,9653

HRK

Croatian kuna

7,3711

IDR

Indonesian rupiah

14 913,76

MYR

Malaysian ringgit

4,7186

PHP

Philippine peso

61,37

RUB

Russian rouble

45,7293

THB

Thai baht

45,764

BRL

Brazilian real

2,9795

MXN

Mexican peso

18,5062

INR

Indian rupee

63,877

---

(1)

Source: reference exchange rate published by the ECB.

---

| 30.1.2009 | EN | Official Journal of the European Union | C 24/8 |
| --- | --- | --- | --- |

30.1.2009

EN

Official Journal of the European Union

C 24/8

---

Summary of Community decisions on marketing authorizations in respect of medicinal products from 1 December 2008 to 31 December 2008

(Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council
   (1)
  )

(2009/C 24/06)

—   Issuing of a marketing authorization (Article 13 of Regulation (EC) No 726/2004): Accepted

| Date of the decision | Name of the medicinal product | INN
  (International Non-Proprietary Name) | Holder of the marketing authorization | Number of the entry in the Community Register | Pharmaceutical form | ATC code
  (Anatomical Therapeutic Chemical Code) | Date of notification |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1.12.2008 | Irbesartan Krka | Irbesartan | KRKA d.d. |
| Šmarješka cesta 6 |
| SLO-8501 Novo mesto |

Date of the decision

Name of the medicinal product

INN

(International Non-Proprietary Name)

Holder of the marketing authorization

Number of the entry in the Community Register

Pharmaceutical form

ATC code

(Anatomical Therapeutic Chemical Code)

Date of notification

1.12.2008

Irbesartan Krka

Irbesartan

KRKA d.d.

Šmarješka cesta 6

SLO-8501 Novo mesto

EU/1/08/480/001-018

Film-coated tablet

C09CA04

3.12.2008

1.12.2008

Vildagliptin/metformin hydrochloride Novartis

Vildagliptin/metformin hydrochloride

| Novartis Europharm Limited |
| --- |
| Wimblehurst Road |
| Horsham |
| West Sussex RH12 5AB |
| United Kingdom |

Novartis Europharm Limited

Wimblehurst Road

Horsham

West Sussex RH12 5AB

United Kingdom

EU/1/08/484/001-018

Film-coated tablet

A10BD08

3.12.2008

1.12.2008

Zomarist

Vildagliptin/metformin hydrochloride

| Novartis Europharm Limited |
| --- |
| Wimblehurst Road |
| Horsham |
| West Sussex RH12 5AB |
| United Kingdom |

Novartis Europharm Limited

Wimblehurst Road

Horsham

West Sussex RH12 5AB

United Kingdom

EU/1/08/483/001-018

Film-coated tablet

A10BD08

3.12.2008

2.12.2008

Kuvan

Sapropterin dihydrochloride

| Merck KgaA |
| --- |
| Frankfurter Straße 250 |
| D-64293 Darmstadt |

Merck KgaA

Frankfurter Straße 250

D-64293 Darmstadt

EU/1/08/481/001-003

Soluble tablet

A16AX07

4.12.2008

17.12.2008

Vidaza

Azacitidine

| Celgene Europe Ltd |
| --- |
| Riverside House |
| Riverside Walk |
| Windsor SL4 1NA |
| United Kingdom |

Celgene Europe Ltd

Riverside House

Riverside Walk

Windsor SL4 1NA

United Kingdom

EU/1/08/488/001

Powder for suspension for injection

L01BC07

22.12.2008

18.12.2008

Pramipexole Teva

Pramipexole

| Teva Pharma B.V. |
| --- |
| Computerweg 10 |
| DR Utrecht 3542 |
| Nederland |

Teva Pharma B.V.

Computerweg 10

DR Utrecht 3542

Nederland

EU/1/08/490/001-016

Tablet

N04B C05

23.12.2008

—   Modification of a marketing authorization (Article 13 of Regulation (EC) No 726/2004): Accepted

| Date of the decision | Name of the medicinal product | Holder of the marketing authorization | Number of the entry in the Community Register | Date of notification |
| --- | --- | --- | --- | --- |
| 1.12.2008 | Sustiva | Bristol-Myers Squibb Pharma EEIG |
| Uxbridge Business Park |
| Sanderson Road |
| Uxbridge UB8 1DH |
| United Kingdom |

Date of the decision

Name of the medicinal product

Holder of the marketing authorization

Number of the entry in the Community Register

Date of notification

1.12.2008

Sustiva

Bristol-Myers Squibb Pharma EEIG

Uxbridge Business Park

Sanderson Road

Uxbridge UB8 1DH

United Kingdom

EU/1/99/110/001-009

3.12.2008

2.12.2008

Axura

| Merz Pharmaceuticals GmbH |
| --- |
| Eckenheimer Landstr. 100-104 |
| D-60318 Frankfurt/Main |

Merz Pharmaceuticals GmbH

Eckenheimer Landstr. 100-104

D-60318 Frankfurt/Main

EU/1/02/218/001-029

4.12.2008

2.12.2008

Ebixa

| H. Lundbeck A/S |
| --- |
| Ottiliavej 9 |
| DK-2500 Valby |

H. Lundbeck A/S

Ottiliavej 9

DK-2500 Valby

EU/1/02/219/001-049

4.12.2008

2.12.2008

Herceptin

| Roche Registration Limited |
| --- |
| 6 Falcon Way |
| Shire Park |
| Welwyn Garden City |
| AL7 1TW |
| United Kingdom |

Roche Registration Limited

6 Falcon Way

Shire Park

Welwyn Garden City

AL7 1TW

United Kingdom

EU/1/00/145/001

4.12.2008

2.12.2008

Rebetol

| Schering Plough Europe |
| --- |
| Rue de Stalle, 73/Stallestraat, 73 |
| B-1180 Bruxelles/Brussel |

Schering Plough Europe

Rue de Stalle, 73/Stallestraat, 73

B-1180 Bruxelles/Brussel

EU/1/99/107/001-005

4.12.2008

4.12.2008

Xigris

| Eli Lilly Nederland B.V., |
| --- |
| Grootslag 1-5 |
| 3991 RA Houten |
| Nederland |

Eli Lilly Nederland B.V.,

Grootslag 1-5

3991 RA Houten

Nederland

EU/1/02/225/001-002

9.12.2008

4.12.2008

Visudyne

| Novartis Europharm Limited |
| --- |
| Wimblehurst Road |
| Horsham |
| West Sussex RH12 5AB |
| United Kingdom |

Novartis Europharm Limited

Wimblehurst Road

Horsham

West Sussex RH12 5AB

United Kingdom

EU/1/00/140/001

9.12.2008

4.12.2008

Noxafil

| SP Europe |
| --- |
| Rue de Stalle, 73/Stallestraat, 73 |
| B-1180 Bruxelles/Brussel |

SP Europe

Rue de Stalle, 73/Stallestraat, 73

B-1180 Bruxelles/Brussel

EU/1/05/320/001

9.12.2008

4.12.2008

Ammonaps

| Swedish Orphan International AB |
| --- |
| Drottninggatan 98 |
| S-111 60 Stockholm |

Swedish Orphan International AB

Drottninggatan 98

S-111 60 Stockholm

EU/1/99/120/001-004

10.12.2008

5.12.2008

Optimark

| Covidien Deutschland GmbH |
| --- |
| Gewerbepark 1 |
| D-93333 Neustadt/Donau |

Covidien Deutschland GmbH

Gewerbepark 1

D-93333 Neustadt/Donau

EU/1/07/398/001-014

9.12.2008

5.12.2008

ViraferonPeg

| Schering Plough Europe |
| --- |
| Rue de Stalle, 73/Stallestraat, 73 |
| B-1180 Bruxelles/Brussel |

Schering Plough Europe

Rue de Stalle, 73/Stallestraat, 73

B-1180 Bruxelles/Brussel

EU/1/00/132/001-050

9.12.2008

5.12.2008

Norvir

| Abbott Laboratories Ltd |
| --- |
| Queenborough |
| Kent ME11 5EL |
| United Kingdom |

Abbott Laboratories Ltd

Queenborough

Kent ME11 5EL

United Kingdom

EU/1/96/016/001

EU/1/96/016/003-004

9.12.2008

5.12.2008

PegIntron

| Schering Plough Europe |
| --- |
| Rue de Stalle, 73/Stallestraat, 73 |
| B-1180 Bruxelles/Brussel |

Schering Plough Europe

Rue de Stalle, 73/Stallestraat, 73

B-1180 Bruxelles/Brussel

EU/1/00/131/001-050

9.12.2008

5.12.2008

MabCampath

| Genzyme Europe B.V. |
| --- |
| Gooimeer 10 |
| 1411 DD Naarden |
| Nederland |

Genzyme Europe B.V.

Gooimeer 10

1411 DD Naarden

Nederland

EU/1/01/193/001-002

9.12.2008

12.12.2008

Mixtard

| Novo Nordisk A/S |
| --- |
| Novo Allé |
| DK-2880 Bagsværd |

Novo Nordisk A/S

Novo Allé

DK-2880 Bagsværd

EU/1/02/231/033-035

16.12.2008

16.12.2008

Prezista

| Janssen-Cilag International NV |
| --- |
| Turnhoutseweg, 30 |
| B-2340 Beerse |

Janssen-Cilag International NV

Turnhoutseweg, 30

B-2340 Beerse

EU/1/06/380/001

18.12.2008

16.12.2008

Faslodex

| AstraZeneca UK Limited |
| --- |
| Alderley Park |
| Macclesfield |
| Cheshire SK10 4TG |
| United Kingdom |

AstraZeneca UK Limited

Alderley Park

Macclesfield

Cheshire SK10 4TG

United Kingdom

EU/1/03/269/001

18.12.2008

16.12.2008

Somavert

| Pfizer Ltd |
| --- |
| Ramsgate Road |
| Sandwich |
| Kent CT 13 9NJ |
| United Kingdom |

Pfizer Ltd

Ramsgate Road

Sandwich

Kent CT 13 9NJ

United Kingdom

EU/1/02/240/001-004

18.12.2008

17.12.2008

Temodal

| Schering Plough Europe |
| --- |
| Rue de Stalle, 73/Stallestraat, 73 |
| B-1180 Bruxelles/Brussel |

Schering Plough Europe

Rue de Stalle, 73/Stallestraat, 73

B-1180 Bruxelles/Brussel

EU/1/98/096/001-012

22.12.2008

17.12.2008

Fareston

| Orion Corporation |
| --- |
| Orionintie 1 |
| FIN-02200 Espoo |

Orion Corporation

Orionintie 1

FIN-02200 Espoo

EU/1/96/004/001-002

22.12.2008

17.12.2008

NovoNorm

| Novo Nordisk A/S |
| --- |
| Novo Allé |
| DK-2880 Bagsværd |

Novo Nordisk A/S

Novo Allé

DK-2880 Bagsværd

EU/1/98/076/004-006

EU/1/98/076/011-013

EU/1/98/076/018-020

EU/1/98/076/022-024

22.12.2008

17.12.2008

Actrapid

| Novo Nordisk A/S |
| --- |
| Novo Allé |
| DK-2880 Bagsværd |

Novo Nordisk A/S

Novo Allé

DK-2880 Bagsværd

EU/1/02/230/013-015

22.12.2008

17.12.2008

Prandin

| Novo Nordisk A/S |
| --- |
| Novo Allé |
| DK-2880 Bagsværd |

Novo Nordisk A/S

Novo Allé

DK-2880 Bagsværd

EU/1/00/162/003-005

EU/1/00/162/009-011

EU/1/00/162/015-017

EU/1/00/162/019-021

22.12.2008

17.12.2008

Avandia

| SmithKline Beecham plc |
| --- |
| 980 Great West Road |
| Brentford |
| Middlesex TW8 9GS |
| United Kingdom |

SmithKline Beecham plc

980 Great West Road

Brentford

Middlesex TW8 9GS

United Kingdom

EU/1/00/137/002-018

22.12.2008

17.12.2008

Hepsera

| Gilead Sciences International Limited |
| --- |
| Cambridge CB21 6GT |
| United Kingdom |

Gilead Sciences International Limited

Cambridge CB21 6GT

United Kingdom

EU/1/03/251/001-002

22.12.2008

17.12.2008

Exjade

| Novartis Europharm Limited |
| --- |
| Wimblehurst Road |
| Horsham |
| West Sussex RH12 5AB |
| United Kingdom |

Novartis Europharm Limited

Wimblehurst Road

Horsham

West Sussex RH12 5AB

United Kingdom

EU/1/06/356/001-009

22.12.2008

17.12.2008

Avonex

| Biogen Idec Ltd |
| --- |
| Innovation House |
| 70 Norden Road |
| Maidenhead |
| Berkshire SL6 4AY |
| United Kingdom |

Biogen Idec Ltd

Innovation House

70 Norden Road

Maidenhead

Berkshire SL6 4AY

United Kingdom

EU/1/97/033/002-004

22.12.2008

17.12.2008

Actraphane

| Novo Nordisk A/S |
| --- |
| Novo Allé |
| DK-2880 Bagsværd |

Novo Nordisk A/S

Novo Allé

DK-2880 Bagsværd

EU/1/02/229/033-035

22.12.2008

19.12.2008

Tysabri

| Elan Pharma International Ltd |
| --- |
| Monksland |
| Athlone County Westmeath |
| Ireland |

Elan Pharma International Ltd

Monksland

Athlone County Westmeath

Ireland

EU/1/06/346/001

23.12.2008

22.12.2008

Telzir

| Glaxo Group Ltd |
| --- |
| Greenford Road |
| Greenford |
| Middlesex UB6 0NN |
| United Kingdom |

Glaxo Group Ltd

Greenford Road

Greenford

Middlesex UB6 0NN

United Kingdom

EU/1/04/282/001-002

24.12.2008

22.12.2008

Arixtra

| Glaxo Group Ltd |
| --- |
| Greenford Road |
| Greenford |
| Middlesex UB6 0NN |
| United Kingdom |

Glaxo Group Ltd

Greenford Road

Greenford

Middlesex UB6 0NN

United Kingdom

EU/1/02/206/001-020

24.12.2008

22.12.2008

Lyrica

| Pfizer Ltd |
| --- |
| Ramsgate Road |
| Sandwich |
| Kent CT 13 9NJ |
| United Kingdom |

Pfizer Ltd

Ramsgate Road

Sandwich

Kent CT 13 9NJ

United Kingdom

EU/1/04/279/001-043

24.12.2008

22.12.2008

Cholestagel

| Genzyme Europe B.V. |
| --- |
| Gooimeer 10 |
| 1411 DD Naarden |
| Nederland |

Genzyme Europe B.V.

Gooimeer 10

1411 DD Naarden

Nederland

EU/1/03/268/001-004

24.12.2008

22.12.2008

Vectibix

| Amgen Europe B.V. |
| --- |
| Minervum 7061 |
| 4817 ZK Breda |
| Nederland |

Amgen Europe B.V.

Minervum 7061

4817 ZK Breda

Nederland

EU/1/07/423/001-003

24.12.2008

22.12.2008

Prezista

| Janssen-Cilag International NV |
| --- |
| Turnhoutseweg, 30 |
| B-2340 Beerse |

Janssen-Cilag International NV

Turnhoutseweg, 30

B-2340 Beerse

EU/1/06/380/001

24.12.2008

22.12.2008

Invanz

| Merck Sharp & Dohme Ltd |
| --- |
| Hertford Road |
| Hoddesdon |
| Hertfordshire EN11 9BU |
| United Kingdom |

Merck Sharp & Dohme Ltd

Hertford Road

Hoddesdon

Hertfordshire EN11 9BU

United Kingdom

EU/1/02/216/001-002

24.12.2008

22.12.2008

Cerezyme

| Genzyme Europe B.V. |
| --- |
| Gooimeer 10 |
| 1411 DD Naarden |
| Nederland |

Genzyme Europe B.V.

Gooimeer 10

1411 DD Naarden

Nederland

EU/1/97/053/001-005

24.12.2008

22.12.2008

Atripla

| Bristol-Myers Squibb and Gilead |
| --- |
| Sciences Limited |
| Unit 13 |
| Stillorgan Industrial Park |
| Blackrock |
| Co. Dublin |
| Ireland |

Bristol-Myers Squibb and Gilead

Sciences Limited

Unit 13

Stillorgan Industrial Park

Blackrock

Co. Dublin

Ireland

EU/1/07/430/001-002

5.1.2009

22.12.2008

Revlimid

| Celgene Europe Limited |
| --- |
| Riverside House |
| Riverside Walk |
| Windsor |
| Berkshire SL4 1NA |
| United Kingdom |

Celgene Europe Limited

Riverside House

Riverside Walk

Windsor

Berkshire SL4 1NA

United Kingdom

EU/1/07/391/001-004

24.12.2008

22.12.2008

Enbrel

| Wyeth Europa Limited |
| --- |
| Huntercombe Lane South Taplow |
| Maidenhead |
| Berkshire SL6 0PH |
| United Kingdom |

Wyeth Europa Limited

Huntercombe Lane South Taplow

Maidenhead

Berkshire SL6 0PH

United Kingdom

EU/1/99/126/001-018

24.12.2008

22.12.2008

Truvada

| Gilead Sciences |
| --- |
| International Limited |
| Cambridge CB21 6GT |
| United Kingdom |

Gilead Sciences

International Limited

Cambridge CB21 6GT

United Kingdom

EU/1/04/305/001-002

24.12.2008

22.12.2008

Evra

| Janssen-Cilag International NV |
| --- |
| Turnhoutseweg, 30 |
| B-2340 Beerse |

Janssen-Cilag International NV

Turnhoutseweg, 30

B-2340 Beerse

EU/1/02/223/001-003

24.12.2008

22.12.2008

Aptivus

| Boehringer Ingelheim International GmbH |
| --- |
| Binger Straße 173 |
| D-55216 Ingelheim am Rhein |

Boehringer Ingelheim International GmbH

Binger Straße 173

D-55216 Ingelheim am Rhein

EU/1/05/315/001

29.12.2008

—   Modification of a marketing authorization (Article 13 of Regulation (EC) No 726/2004): Rejected

| Date of the decision | Name of the medicinal product | Holder of the marketing authorization | Number of the entry in the Community Register | Date of notification |
| --- | --- | --- | --- | --- |
| 8.12.2008 | Xeristar | Boehringer Ingelheim International GmbH |
| Binger Straße 173 |
| D-55216 Ingelheim am Rhein |

Date of the decision

Name of the medicinal product

Holder of the marketing authorization

Number of the entry in the Community Register

Date of notification

8.12.2008

Xeristar

Boehringer Ingelheim International GmbH

Binger Straße 173

D-55216 Ingelheim am Rhein

EU/1/04/297/001-008

10.12.2008

8.12.2008

Cymbalta

| Eli Lilly Nederland B.V. |
| --- |
| Grootslag 1-5 |
| 3991 RA Houten |
| Nederland |

Eli Lilly Nederland B.V.

Grootslag 1-5

3991 RA Houten

Nederland

EU/1/04/296/001-009

10.12.2008

—   Withdrawal of a marketing authorization (Article 13 of Regulation (EC) No 726/2004)

| Date of the decision | Name of the medicinal product | Holder of the marketing authorization | Number of the entry in the Community Register | Date of notification |
| --- | --- | --- | --- | --- |
| 5.12.2008 | Parareg | Dompé Biotec S.p.A. |
| Via San Martino, 12 |
| I-20122 Milano |

Date of the decision

Name of the medicinal product

Holder of the marketing authorization

Number of the entry in the Community Register

Date of notification

5.12.2008

Parareg

Dompé Biotec S.p.A.

Via San Martino, 12

I-20122 Milano

EU/1/04/293/001-012

9.12.2008

5.12.2008

Neupopeg

| Dompé Biotec S.p.A. |
| --- |
| Via San Martino, 12 |
| I-20122 Milano |

Dompé Biotec S.p.A.

Via San Martino, 12

I-20122 Milano

EU/1/02/228/001-003

9.12.2008

5.12.2008

Nespo

| Dompé Biotec S.p.A. |
| --- |
| Via San Martino, 12 |
| I-20122 Milano |

Dompé Biotec S.p.A.

Via San Martino, 12

I-20122 Milano

EU/1/01/184/001-073

9.12.2008

—   Issuing of a marketing authorization (Article 38 of Regulation (EC) No 726/2004): Accepted

| Date of the decision | Name of the medicinal product | INN
  (International Non-Proprietary Name) | Holder of the marketing authorization | Number of the entry in the Community Register | Pharmaceutical form | ATC code
  (Anatomical Therapeutic Chemical Code) | Date of notification |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 9.12.2008 | Acticam | Meloxicam | Omnipharm Ltd |
| The Spire |
| Egypt Road |
| Nottingham NG7 7GD |
| United Kingdom |

Date of the decision

Name of the medicinal product

INN

(International Non-Proprietary Name)

Holder of the marketing authorization

Number of the entry in the Community Register

Pharmaceutical form

ATC code

(Anatomical Therapeutic Chemical Code)

Date of notification

9.12.2008

Acticam

Meloxicam

Omnipharm Ltd

The Spire

Egypt Road

Nottingham NG7 7GD

United Kingdom

EU/2/08/088/001-003

Oral suspension

QM01AC06

11.12.2008

EU/2/08/088/004

Solution for injection

16.12.2008

Onsior

Robenacoxib

| Novartis Animal Health UK Ltd |
| --- |
| Frimley Business Park |
| Frimley/Camberley |
| Surrey GU16 7SR |
| United Kingdom |

Novartis Animal Health UK Ltd

Frimley Business Park

Frimley/Camberley

Surrey GU16 7SR

United Kingdom

EU/2/08/089/001-019

Tablet

QM01AH91

18.12.2008

EU/2/08/089/020

Solution for injection

—   Modification of a marketing authorization (Article 38 of Regulation (EC) No 726/2004): Accepted

| Date of the decision | Name of the medicinal product | Holder of the marketing authorization | Number of the entry in the Community Register | Date of notification |
| --- | --- | --- | --- | --- |
| 5.12.2008 | Locatim | Biokema Anstalt |
| Aeulestraße 38 |
| FL-9490 Vaduz, |
| Fürstentum Liechtenstein |

Date of the decision

Name of the medicinal product

Holder of the marketing authorization

Number of the entry in the Community Register

Date of notification

5.12.2008

Locatim

Biokema Anstalt

Aeulestraße 38

FL-9490 Vaduz,

Fürstentum Liechtenstein

EU/2/99/011/001

10.12.2008

9.12.2008

Flexicam

| Omnipharm Ltd |
| --- |
| The Spire |
| Egypt Road |
| Nottingham NG7 7GD |
| United Kingdom |

Omnipharm Ltd

The Spire

Egypt Road

Nottingham NG7 7GD

United Kingdom

EU/2/06/058/004

11.12.2008

16.12.2008

Equilis StrepE

| Intervet International B.V. |
| --- |
| Wim de Körverstraat 35 |
| 5831 AN Boxmeer |
| Nederland |

Intervet International B.V.

Wim de Körverstraat 35

5831 AN Boxmeer

Nederland

EU/2/04/043/001

18.12.2008

Anyone wishing to consult the public assessment report on the medicinal products in question and the decisions relating thereto is invited to contact:

| The European Medicines Agency |
| --- |
| 7 Westferry Circus |
| Canary Wharf |
| London E14 4HB |
| United Kingdom |

The European Medicines Agency

7 Westferry Circus

Canary Wharf

London E14 4HB

United Kingdom

---

(1)  OJ L 136, 30.4. 2004, p. 1.

---

V Announcements

PROCEDURES RELATING TO THE IMPLEMENTATION OF THE COMPETITION POLICY

Commission

| 30.1.2009 | EN | Official Journal of the European Union | C 24/14 |
| --- | --- | --- | --- |

30.1.2009

EN

Official Journal of the European Union

C 24/14

---

Prior notification of a concentration

(Case COMP/M.5355 — BASF/Ciba)

(Text with EEA relevance)

(2009/C 24/07)

| 1. | On 22 January 2009, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which BASF SE (‘BASF’, Germany) acquires within the meaning of Article 3(1)(b) of the Council Regulation control of the whole of Ciba Holding AG (‘Ciba’, Switzerland) by way of public bid announced on 15 September 2008. |
| --- | --- |

1.

On 22 January 2009, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which BASF SE (‘BASF’, Germany) acquires within the meaning of Article 3(1)(b) of the Council Regulation control of the whole of Ciba Holding AG (‘Ciba’, Switzerland) by way of public bid announced on 15 September 2008.

| 2. | The business activities of the undertakings concerned are:






  — | for BASF: chemicals, plastics, performance products, agricultural products and fine chemicals, |
| --- | --- | --- |

2.

The business activities of the undertakings concerned are:

—

for BASF: chemicals, plastics, performance products, agricultural products and fine chemicals,

| — | for Ciba: specialty chemicals. |
| --- | --- |

—

for Ciba: specialty chemicals.

| 3. | On preliminary examination, the Commission finds that the notified transaction could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved.

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax ((32-2) 296 43 01 or 296 72 44) or by post, under reference number COMP/M.5355 — BASF/Ciba, to the following address:





  European Commission |
| --- | --- |
| Directorate-General for Competition |
| Merger Registry |
| J-70 |
| B-1049 Brussels |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax ((32-2) 296 43 01 or 296 72 44) or by post, under reference number COMP/M.5355 — BASF/Ciba, to the following address:

European Commission

Directorate-General for Competition

Merger Registry

J-70

B-1049 Brussels

---

(1)  OJ L 24, 29.1.2004, p. 1.

---

| 30.1.2009 | EN | Official Journal of the European Union | C 24/15 |
| --- | --- | --- | --- |

30.1.2009

EN

Official Journal of the European Union

C 24/15

---

Prior notification of a concentration

(Case COMP/M.5432 — Credit Mutuel/Cofidis)

(Text with EEA relevance)

(2009/C 24/08)

| 1. | On 21 January 2009, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertaking Banque Federative du Credit Mutuel S.A. (‘Credit Mutuel’, France) acquires within the meaning of Article 3(1)(b) of the Council Regulation sole control of Cofidis Participations, S.A. (‘Cofidis’, France) by way of purchase of shares. |
| --- | --- |

1.

On 21 January 2009, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertaking Banque Federative du Credit Mutuel S.A. (‘Credit Mutuel’, France) acquires within the meaning of Article 3(1)(b) of the Council Regulation sole control of Cofidis Participations, S.A. (‘Cofidis’, France) by way of purchase of shares.

| 2. | The business activities of the undertakings concerned are:






  — | for undertaking Credit Mutuel: products and services associated to the banking and insurance sectors mainly in France, |
| --- | --- | --- |

2.

The business activities of the undertakings concerned are:

—

for undertaking Credit Mutuel: products and services associated to the banking and insurance sectors mainly in France,

| — | for Cofidis: products and services associated to the consumer credit in France and internationally. |
| --- | --- |

—

for Cofidis: products and services associated to the consumer credit in France and internationally.

| 3. | On preliminary examination, the Commission finds that the notified transaction could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved.

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax ((32-2) 296 43 01 or 296 72 44) or by post, under reference number COMP/M.5432 — Credit Mutuel/Cofidis, to the following address:





  European Commission |
| --- | --- |
| Directorate-General for Competition |
| Merger Registry |
| J-70 |
| B-1049 Brussels |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax ((32-2) 296 43 01 or 296 72 44) or by post, under reference number COMP/M.5432 — Credit Mutuel/Cofidis, to the following address:

European Commission

Directorate-General for Competition

Merger Registry

J-70

B-1049 Brussels

---

(1)  OJ L 24, 29.1.2004, p. 1.

---

| 30.1.2009 | EN | Official Journal of the European Union | C 24/16 |
| --- | --- | --- | --- |

30.1.2009

EN

Official Journal of the European Union

C 24/16

---

Prior notification of a concentration

(Case COMP/M.5471 — Goldman Sachs/Constellation Energy Commodities)

Candidate case for simplified procedure

(Text with EEA relevance)

(2009/C 24/09)

| 1. | On 23 January 2009, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertaking J. Aron & Company, controlled by The Goldman Sachs Group, Inc (‘GS’, USA), acquires within the meaning of Article 3(1)(b) of the Council Regulation control of substantially all of the assets of the international commodities business of Constellation Energy Commodities Group, Inc., controlled by Constellation Energy Group, Inc. (‘International Commodities Business of CECG’, USA). |
| --- | --- |

1.

On 23 January 2009, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertaking J. Aron & Company, controlled by The Goldman Sachs Group, Inc (‘GS’, USA), acquires within the meaning of Article 3(1)(b) of the Council Regulation control of substantially all of the assets of the international commodities business of Constellation Energy Commodities Group, Inc., controlled by Constellation Energy Group, Inc. (‘International Commodities Business of CECG’, USA).

| 2. | The business activities of the undertakings concerned are:






  — | for GS: banking, securities and investment services, |
| --- | --- | --- |

2.

The business activities of the undertakings concerned are:

—

for GS: banking, securities and investment services,

| — | for the International Commodities Business of CECG: trading and ancillary services with a primary focus on global coal trading and freights services. |
| --- | --- |

—

for the International Commodities Business of CECG: trading and ancillary services with a primary focus on global coal trading and freights services.

| 3. | On preliminary examination, the Commission finds that the notified transaction could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax ((32-2) 296 43 01 or 296 72 44) or by post, under reference number COMP/M.5471 — Goldman Sachs/Constellation Energy Commodities, to the following address:





  European Commission |
| --- | --- |
| Directorate General for Competition |
| Merger Registry |
| J-70 |
| B-1049 Brussels |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax ((32-2) 296 43 01 or 296 72 44) or by post, under reference number COMP/M.5471 — Goldman Sachs/Constellation Energy Commodities, to the following address:

European Commission

Directorate General for Competition

Merger Registry

J-70

B-1049 Brussels

---

(1)  OJ L 24, 29.1.2004, p. 1.

(2)  OJ C 56, 5.3.2005, p. 32.

---

| 30.1.2009 | EN | Official Journal of the European Union | C 24/17 |
| --- | --- | --- | --- |

30.1.2009

EN

Official Journal of the European Union

C 24/17

---

Prior notification of a concentration

(Case COMP/M.5370 — CEZ/Akkok/Sedas/Akenerji)

Candidate case for simplified procedure

(Text with EEA relevance)

(2009/C 24/10)

| 1. | On 22 January 2009, the Commission received a notification of a proposed concentration pursuant to Article 4 and following a referral pursuant to Article 4(5) of Council Regulation (EC) No 139/2004 (1) by which CEZ, a.s. (‘CEZ’, Czech Republic) belonging to the CEZ Group and Akkok Sanayi Yatirim ve Gelistirme A.S. (‘Akkok’, Turkey) acquire within the meaning of Article 3(1)(b) of the Council Regulation joint control of the undertaking Akenerji Elektrik Uretim A.S. (‘Akenerji’, Turkey) by way of purchase of shares. Subsequently, CEZ and Akkok acquire within the meaning of Article 3(1)(b) of the Council Regulation joint control of the undertaking Sakarya Elektrik Dagitim A.S. (‘Sedas’, Turkey) by way of purchase of shares. |
| --- | --- |

1.

On 22 January 2009, the Commission received a notification of a proposed concentration pursuant to Article 4 and following a referral pursuant to Article 4(5) of Council Regulation (EC) No 139/2004 (1) by which CEZ, a.s. (‘CEZ’, Czech Republic) belonging to the CEZ Group and Akkok Sanayi Yatirim ve Gelistirme A.S. (‘Akkok’, Turkey) acquire within the meaning of Article 3(1)(b) of the Council Regulation joint control of the undertaking Akenerji Elektrik Uretim A.S. (‘Akenerji’, Turkey) by way of purchase of shares. Subsequently, CEZ and Akkok acquire within the meaning of Article 3(1)(b) of the Council Regulation joint control of the undertaking Sakarya Elektrik Dagitim A.S. (‘Sedas’, Turkey) by way of purchase of shares.

| 2. | The business activities of the undertakings concerned are:






  — | for CEZ: generation, distribution and sale of electricity, coal mining, among other activities, |
| --- | --- | --- |

2.

The business activities of the undertakings concerned are:

—

for CEZ: generation, distribution and sale of electricity, coal mining, among other activities,

| — | for Akkok: energy, chemicals, textile, real estate, among others, |
| --- | --- |

—

for Akkok: energy, chemicals, textile, real estate, among others,

| — | for Akenerji: generation of electricity and steam, |
| --- | --- |

—

for Akenerji: generation of electricity and steam,

| — | for Sedas: distribution and sale of electricity. |
| --- | --- |

—

for Sedas: distribution and sale of electricity.

| 3. | On preliminary examination, the Commission finds that the notified transaction could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax ((32-2) 296 43 01 or 296 72 44) or by post, under reference number COMP/M.5370 — CEZ/Akkok/Sedas/Akenerji, to the following address:





  European Commission |
| --- | --- |
| Directorate-General for Competition |
| Merger Registry |
| J-70 |
| B-1049 Brussels |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax ((32-2) 296 43 01 or 296 72 44) or by post, under reference number COMP/M.5370 — CEZ/Akkok/Sedas/Akenerji, to the following address:

European Commission

Directorate-General for Competition

Merger Registry

J-70

B-1049 Brussels

---

(1)  OJ L 24, 29.1.2004, p. 1.

(2)  OJ C 56, 5.3.2005, p. 32.

---

30.1.2009

| 30.1.2009 | EN | Official Journal of the European Union | C 24/s3 |
| --- | --- | --- | --- |

EN

Official Journal of the European Union

C 24/s3

---

NOTE TO THE READER

The institutions have decided no longer to quote in their texts the last amendment to cited acts.

Unless otherwise indicated, references to acts in the texts published here are to the version of those acts currently in force.

---